SCHEMBL3615845

SCHEMBL3615845

O=C(O)c1ccc(-c2ccc(S(=O)(=O)Nc3nc(CC(=O)N4CCOCC4)cs3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.61
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
PKM P14618 1/20 0.43
PHGDH O43175 2/20 0.43
CTPS1 P17812 3/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 2/20 0.42
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ESR1 P03372 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614418 0.92 HSD11B1 (0.63) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3252937 0.90 HSD11B1 (0.63) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3619549 0.90 HSD11B1 (0.70) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3615296 0.88 HSD11B1 (0.67) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3620848 0.88 HSD11B1 (0.60) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3622071 0.87 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3606758 0.86 HSD11B1 (0.65) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3619100 0.86 HSD11B1 (0.65) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3621059 0.86 HSD11B1 (0.68) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9
SCHEMBL3611275 0.85 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.